Table 1.

Characteristics of RA patients for whom analysis of IL-17-positive CD4 T cells in paired blood and synovial fluid (top), and paired blood and synovium (bottom) was performed.

				Treatment						% CD3+CD4+ IL17+
Subject	RF	ACPA	Disease duration, years	DMARD	Anti-TNF	Steroid	ESR, mm/hr	CRP, mg/l	DAS28 (ESR)	PBMC	SFMC
1	+ve	+ve	<1	MTX, HCQ	N	N	39	15	6.20	1.95	2.52
2	+ve	+ve	2	MTX, HCQ	N	N	61	8	7.01	1.09	0.82
3	+ve	+ve	1	N	N	N	21	7	4.18	2.36	2.17
4	+ve	-ve	23	MTX	N	N	18	11	5.83	0.73	0.79
5	+ve	-ve	45	MTX	N	N	60	11	5.27	0.63	0.53
6	+ve	+ve	5	MTX, SSZ	N	N	69	93	5.48	2.34	2.84
7	+ve	+ve	4	N	Y	Y	28	30	3.51	3.48	1.17
8	+ve	+ve	<1	MTX, HCQ	N	Y	63	72	6.14	1.59	1.44
9	+ve	+ve	5	N	Y	Y	32	12	5.62	1.30	7.90
10	+ve	+ve	<1	MTX	Y	N	80	71	6.08	0.73	5.18
11	-ve	+ve	1	N	N	N	10	15	5.76	0.86	3.48
12	+ve	+ve	5	MTX	Y	Y	24	24	4.42	1.06	1.06
13	-ve	-ve	6	HCQ	N	N	81	92	4.39	0.37	4.45
14	+ve	+ve	1	MTX	N	Y	17	16	4.48	0.49	0.46
				Treatment						% CD3+CD4+ IL17+
Subject	RF	ACPA	Disease duration, years	DMARD	Anti-TNF	Steroid	ESR, mm/hr	CRP, mg/l	DAS28 (ESR)	PBMC	SVMC
1	+ve	+ve	16	N	Y	N	20	20	3.83	0.77	0.55
2	+ve	+ve	4	N	Y	Y	13	9	4.95	0.57	0.48
3	+ve	+ve	5	N	Y	Y	13	3	4.50	1.63	0.78
4	-ve	+ve	8	MTX	Y	N	12	0	3.57	1.49	1.08
5	+ve	+ve	20	N	N	Y	89	24	6.03	2.63	0.91
6	+ve	+ve	23	N	N	Y	45	57	5.86	0.08	0.24
7	+ve	+ve	20	SSZ	N	N	31	11	4.33	0.73	0.81
8	+ve	+ve	5	N	Y	Y	15	3	4.55	0.29	1.17
9	-ve	-ve	15	N	Y	N	115	22	6.19	1.37	0.99
10	-ve	+ve	1	LEF	N	N	10	15	5.76	1.65	0.48

-ve, negative; +ve, positive; ACPA, anti-CCP antibodies; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; N, no; PB, peripheral blood; RF, rheumatoid factor; SF, synovial fluid; SSZ, sulfasalazine; SVMC, synovium mononuclear cells; Y, yes.